Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 330

Posts Tagged ‘poxel’

Poxel Announces Updates to its Management Team

Posted by fidest press agency su martedì, 3 dicembre 2019

POXEL SA (Euronext: POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced changes in its management team, with the appointment of Quentin Durand as Chief Legal Officer, and the departure of Christophe Arbet-Engels, MD, PhD, MBA, Chief Medical Officer and Executive Vice President (EVP) Late Development & Medical Affairs. Quentin Durand joined Poxel from the international law firm of Dechert LLP where he served as a lawyer since 2015 in the Paris office. While at Dechert LLP, Quentin focused on corporate and securities matters with an emphasis on capital markets, including public company reporting and governance and worked closely with Poxel during this time. He was also involved in various merger and acquisition and equity capital market transactions both domestic and cross border across a wide range of industry sectors. Prior to working at Dechert LLP, Quentin served as a legal officer within the corporate finance division of the Autorité des marchés financiers and acted as a prosecutor before the Autorité des marchés financiers enforcement committee.“We are delighted to welcome Quentin to the Poxel team. He knows the Company very well from the time he spent at Dechert LLP where he was actively involved in supporting Poxel on corporate, securities and governance matters,” said Thomas Kuhn, CEO of Poxel. “As Poxel continues to advance its business strategy, his legal expertise will be invaluable in helping the Company to execute against its plan.”Additionally, Christophe Arbet-Engels, MD, PhD, MBA, Chief Medical Officer and EVP Late Development & Medical Affairs, has left the Company to pursue other career opportunities.“Christophe brought a wealth of expertise to Poxel. He led the Imeglimin TIMES program in Japan, which is now coming to completion and has reported successful clinical results from the TIMES 1 and TIMES 3 trials,” said Thomas Kuhn. “We would like to thank Christophe for the valuable contributions he made to Poxel and we wish him the very best in his future endeavors.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Poxel Announces Presentation of PXL065 Data at the 2019 NASH-TAG Conference

Posted by fidest press agency su martedì, 8 gennaio 2019

POXEL SA (Euronext: POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that an oral presentation, including data for PXL065, the deuterium-stabilized R-stereoisomer of pioglitazone, was made at the 2019 NASH-TAG Conference. The presentation titled “PXL065, Pioglitazone (pio), and Thiazolidinediones (TZDs): Unravelling Pio’s superior efficacy for NASH and role of stereoisomers” was given on January 5, 2019 in Park City, Utah.The presentation highlighted key aspects related to the pharmacokinetic (PK) and pharmacodynamic (PD) role of stereoisomers within the class of compounds known as TZDs and the potential relevance for the treatment of NASH. Representative TZDs included rosiglitazone, pioglitazone and lobeglitazone, all of which are a mixture of interconverting R- and S- stereoisomers that have exhibited varying levels of efficacy for NASH in animal and/or human studies.Key findings presented included: 1) a comparison of the striking species-dependent stereoselectivity of the PK for pioglitazone with other TZDs, 2) a comparison of unexpected differences in peroxisome proliferator-activated receptor gamma (PPARγ) activity with the eight stereoisomers that make up pioglitazone and its two active metabolites and 3) stabilization of pioglitazone’s stereoisomers with deuterium to characterize and identify R-pioglitazone as the preferred stereoisomer for the treatment of NASH.Data presented demonstrated that each stereoisomer of pioglitazone and its active metabolites exhibits different PPARγ activity. The presentation also included data showing that PXL065 is a mitochondrial pyruvate carrier (MPC) inhibitor without PPARγ activity in a cofactor recruitment assay. In mouse models, PXL065 demonstrated the hepatic benefits observed with pioglitazone in NASH patients. In preclinical models, PXL065 exhibited little or no weight gain or fluid retention, side effects mainly associated with the PPARγ active, S-pioglitazone.Pioglitazone (Actos®*), a drug approved for the treatment of type 2 diabetes, has demonstrated therapeutic efficacy for NASH, even in patients with advanced fibrosis. However, its therapeutic use and potential have been limited due to the PPARγ-related side effects of weight gain, bone fractures and fluid retention. PXL065 offers a proprietary new approach for the treatment of NASH. PXL065 has the potential to preserve the pharmacological benefits of pioglitazone required for the treatment of NASH, such as a reduction of hepatic steatosis, inflammation, ballooning and fibrosis and could reduce PPARγ-related side effects that are thought to be associated with S-pioglitazone.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Poxel Appoints Takashi Kaneko, MD, PhD, as Senior Vice President Medical and President of Poxel Japan K.K.

Posted by fidest press agency su sabato, 15 settembre 2018

POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that Takashi Kaneko, MD, PhD, has joined Poxel as Senior Vice President Medical and President of Poxel Japan K.K., effective September 1, 2018, to lead the Company’s drug development and medical affairs activities as well as the team in Japan. In addition, the Company has established a wholly-owned Japanese subsidiary in Tokyo.
“Japan has been a strategic focus for Poxel and we have made significant progress in the development of Imeglimin for the treatment of type 2 diabetes for this market. This includes a robust Phase 2b program, which resulted in the strategic partnership with Sumitomo Dainippon Pharma for Japan, China and eleven other Asian countries. We are also advancing the Imeglimin Phase 3 TIMES program in Japan, with our partner Sumitomo, for which we expect the first data results in the first half of 2019,” said Thomas Kuhn, CEO of Poxel. “The addition of Dr. Kaneko to our team with his medical affairs and clinical development expertise and knowledge of the Japanese market is of great importance to Poxel today and moving forward as we continue to expand our efforts in Japan through our newly established subsidiary in Tokyo.”
Dr. Kaneko brings to Poxel over 33 years of experience including pharmaceutical industry experience with a focus on medical affairs and clinical development ranging from product evaluation, development and post-commercial launch, and clinical practice and medical research experience. Dr. Kaneko joins Poxel from Janssen Pharmaceutical K.K., where he was Head of Medical Affairs. Prior to Janssen Pharmaceutical K.K., he was the Department Head of the Medical Excellence Department in the Medical Division at Novartis K.K. Dr. Kaneko also held several senior-level positions at Santen, which included the areas of Compliance, Global Clinical Development and Medical Affairs, Head of Global Research and Development as well as other research and development-related positions. In addition, Dr. Kaneko was a Vice President, Medical Director at Sanofi-Aventis K.K., and served in clinical development roles at Bristol-Myers K.K., BMS, Japan. Dr. Kaneko holds an MD and PhD degree from the University of Tokyo, Tokyo, Japan.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Poxel Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference

Posted by fidest press agency su sabato, 7 aprile 2018

POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today that it will be featured as a presenting company at the H.C. Wainwright Annual Global Life Sciences Conference. The conference is being held on April 8-10th at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
Poxel will present a corporate overview on Tuesday, April 10th at 9:50-10:15 AM CEST in Salon Atlantique-Meridional (2nd Floor) and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. To access the webcast, please visit the following link http://wsw.com/webcast/hcw2/poxel.pa/. The webcast replay will remain available for 90 days following the live presentation.
Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., EU and Japan. Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Phase 3 TIMES program for the treatment of type 2 diabetes in Japan. Our partner Roivant Sciences will be responsible for Imeglimin’s development and commercialization in countries outside of Poxel’s partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. Our second program, PXL770, a first in class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in Phase 1 and we plan on developing it for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, http://www.poxelpharma.com)

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »